RxDoctor Payments Data

Joseph Kimball, DO

Family Medicine · Winterset, IANPI 1447362991

Payments from drug & device makers

$377in general payments, 2019–2025

Across 18 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$100
  • Lilly USA, LLC$73
  • Abbott$59
  • Boehringer Ingelheim$34
  • Dexcom, Inc.$31
  • Sanofi Pasteur Inc.$22
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$35895%
  • Education$195%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$377 in reported general payments places this provider in the 65th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$4,810
Medicare patients
21
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$155,325
JardianceEmpagliflozin135$135,424
OzempicSemaglutide126$130,360
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$63,910
XareltoRivaroxaban55$42,787
MounjaroTirzepatide24$24,435
Breo ElliptaFluticasone/Vilanterol33$20,860
Tresiba Flextouch U-100Insulin Degludec38$19,016
TrulicityDulaglutide14$15,827
EntrestoSacubitril/Valsartan12$13,517
MyrbetriqMirabegron17$13,096
FarxigaDapagliflozin Propanediol11$12,125
DuleraMometasone/Formoterol14$4,960
Potassium Chloride257$4,825
Duloxetine Hcl275$4,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$34$135,424135 claims
Novo NordiskOzempic$15$130,360126 claims
Lilly USA, LLCMounjaro, Trulicity$73$40,26138 claims
NovartisEntresto$100$13,51712 claims
Astellas Pharma US IncMyrbetriq$13$13,09617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Winterset

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →